Cervical cancer and ovarian cancer are not the same disease. They start in different organs, have different causes, produce different symptoms, and are detected in completely different ways. Both fall under the umbrella of gynecologic cancers, which is why they’re sometimes confused, but the similarities largely end there.
They Start in Different Organs
The cervix is the lower, narrow part of the uterus that opens into the vagina. It’s essentially the gateway between the vagina and the uterus. Cervical cancer begins in the cells lining this passageway.
The ovaries sit on either side of the uterus, deeper in the pelvis. Their job is to release eggs and produce the hormones estrogen and progesterone. Ovarian cancer starts in or near these organs, and many cases actually originate in the fallopian tubes rather than the ovaries themselves. Despite sharing a general neighborhood in the reproductive system, the cervix and ovaries develop from entirely different tissue during embryonic development, which is part of why cancers in these two locations behave so differently.
The Causes Are Almost Entirely Different
Cervical cancer is caused by a virus. About 99.7% of cervical cancer cases result from a persistent infection with high-risk strains of human papillomavirus (HPV), a sexually transmitted infection. This makes cervical cancer one of the most preventable cancers in existence, because the infection that causes it can be vaccinated against and detected through screening years before cancer develops.
Ovarian cancer has no single dominant cause. The strongest known risk factor is an inherited mutation in the BRCA1 or BRCA2 genes. Women who carry a harmful BRCA1 mutation have a 39% to 58% lifetime risk of developing ovarian cancer, compared to about 1.1% in the general population. BRCA2 mutations carry a 13% to 29% lifetime risk. But most women who develop ovarian cancer don’t have these mutations. Other factors that raise the risk include older age (risk climbs steeply after 45 and peaks between 75 and 79), obesity, endometriosis, diabetes, hormone replacement therapy, smoking, and asbestos exposure.
Symptoms Show Up Differently
Cervical cancer tends to announce itself through abnormal vaginal bleeding or unusual discharge. This might mean bleeding between periods, after sex, or after menopause. Because the cervix is accessible during a pelvic exam and screening, cervical cancer is often caught before symptoms even appear.
Ovarian cancer is far more subtle. Its hallmark symptoms are bloating, feeling full quickly when eating, and abdominal or back pain. You might also notice pelvic pressure, more frequent urination, or constipation. The problem is that all of these symptoms overlap with dozens of everyday conditions, from digestive issues to urinary tract problems. This vagueness is a major reason ovarian cancer is typically diagnosed at a later stage.
Screening Is Available for One but Not the Other
Cervical cancer has one of the most effective screening programs in medicine. The Pap test and the HPV test can detect precancerous changes in cervical cells years before they become cancer. Current guidelines recommend starting Pap tests at age 21, repeating every three years through age 29, then switching to either an HPV test alone or a combined HPV and Pap test every five years from age 30 to 65. Women over 65 with a history of normal results can typically stop screening altogether.
Ovarian cancer has no reliable screening test. The U.S. Preventive Services Task Force actually recommends against routine screening for ovarian cancer in women who aren’t at high risk. The two tests that exist, transvaginal ultrasound and a blood marker called CA-125, produce too many false positives without reducing deaths from the disease. A positive result on these tests often leads to unnecessary surgery to determine whether cancer is actually present, since a tissue biopsy isn’t sufficient for ovarian cancer. The ovary or ovaries typically need to be surgically removed just to make a diagnosis. These tests are used when a woman already has suspicious symptoms, not as routine screening.
Prevention Options Differ Dramatically
The HPV vaccine has transformed cervical cancer prevention. A large Swedish study of nearly 1.7 million women found that girls vaccinated before age 17 had a nearly 90% reduction in cervical cancer incidence compared to unvaccinated women. Even when accounting for other risk factors, vaccinated women overall had a 63% lower chance of being diagnosed with cervical cancer. Combined with regular screening, the HPV vaccine makes cervical cancer one of the few cancers with a realistic path to near-elimination.
Preventing ovarian cancer is more complicated. Women with BRCA mutations sometimes choose to have their ovaries and fallopian tubes surgically removed to dramatically lower their risk. Oral contraceptives reduce ovarian cancer risk by about 50% in both the general population and women with BRCA mutations, though this benefit must be weighed against other health considerations. Beyond that, there is no vaccine, no screening program, and no single intervention that reliably prevents it.
Survival Rates Reflect These Differences
Cervical cancer has an overall five-year survival rate of 68.8%. When caught while still localized to the cervix, that number jumps to 91.8%. Once it has spread to distant parts of the body, survival drops to 20.5%. The availability of screening means a significant portion of cervical cancers are caught early.
Ovarian cancer has an overall five-year survival rate of 52.0%. Localized ovarian cancer has a 91.9% survival rate, nearly identical to localized cervical cancer. The critical difference is that ovarian cancer is far less likely to be caught at that early stage because of the lack of screening and the vagueness of its symptoms. When diagnosed after it has spread distantly, the five-year survival rate is 31.5%.
Both cancers are highly treatable when found early. The gap in overall survival largely comes down to detection: cervical cancer has tools that catch it sooner, while ovarian cancer often goes unnoticed until it has progressed. This single difference, more than anything about the biology of the tumors themselves, shapes outcomes for the women diagnosed with each disease.